Overview

TBP has one of the most advanced pipelines among companies in North America, working with Health Canada and the FDA on clinical trial programs with cannabinoid-derived medicines.

TBP’s cannabinoid-derived medicines target medical indications representing addressable markets of over $20 billion, supported by the urgent need for non-opioid alternatives to treat pain and inflammation.

TBP is building sustainable value for shareholders with an extensive and leading portfolio of cannabinoid-derived drugs, valuable intellectual property, spearheaded by a solid scientific and regulatory team.